Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

Um, with all due respect, if an antibiotic isn't working for ABSSSI at 48-72 hours then the patient needs a different intervention. If brilacidin treated patients are responding as well as daptomycin patients 48-72 hours after initiating treatment, then this is extremely important information. If the response is sustained and the secondary endpoint of ABSSSI treatment is achieved after 7-14 days at a rate comparable to daptomycin, then brilacidin is a homerun. The September 9 addressed the secondary endpoint:

The data shows that by Day 7, the average cure rate for all four treatment arms was higher than what was observed in the phase 2a study, and similar to – if not higher than – cure rates reported for common ABSSSI drugs, as well as those approved this year.

At that time, I commented that the PR was only addressing the secondary endpoint which was fairly easy to assess. The October 23rd press release focuses on the primary endpoint which is more difficult to measure and compile data.

Looks great, sounds great. I'm looking forward to seeing all the data, including the number of patients in each group that required secondary intervention(s).